





Welcome back!

# Group Discussions

Dr. Mohamed Sirdar, WOAH SRR-SA














# **G-D (1): Quality of Veterinary Medicinal Products**















#### Q-1: IMPLEMENTATION OF QUALITY OF VMPS STANDARDS

Which Standards and Guidelines you are using/implemented in your national system or intend to use?

#### Q-2: GAPS AND CHALLENGES FOR IMPLEMENTATION OF QUALITY OF VMPS STANDARDS

Could you please identify the 3 main gaps and challenges for implementation of Quality of VMPs standards?

#### Q-3: OPPORTUNITIES FOR IMPLEMENTATION OF QUALITY OF VMPS STANDARDS

Do you see any opportunities in the future to implement Quality VMPs Standards (WOAH- Vaccines and AMR related) and VICH Guidelines? [explore enablers and challenges for implementation; explore also related guidelines if relevant]

#### Q-4: JOINT COMMITMENT FOR IMPLEMENTATION OF QUALITY OF VMPS STANDARDS

Please suggest any possible joint commitment based on the questions above.

- AMU Surveillance
- Pharmacovigilance and postmarket surveillance
- Quality assurance labs
- Vaccines and diagnostic kits
- VMPs containing antimicrobial agents
- VICH guidelines
- Other, please specify...













### **Groups & Facilitators**

G-1

Botswana

Ghana

Kenya

Liberia

Seychelles

Zambia

G-2

Egypt

Ethiopia?

Lesotho

Malawi

Nigeria

South Africa

G-3

Eritrea

Namibia

**Tanzania** 

Uganda

G-4

eSwatini

Mauritius

Rwanda

South Sudan

Zimbabwe

Somalia



F-1

Mária Szabó

G. Thobokwe

F-2

Jane Lwoyero

Ana Mateus

F-3

**Mohamed Sirdar** 

Liezl Kock

F-4

Francesco Valentini

A. Ayoyi













G-D (2): Registration, authorisation, and harmonisation of regulations















#### Q-1: IMPLEMENTATION

Do you have any regulatory system and national procedure to register/authorise VMPs?

Do you take part any community registration/authorisation procedure(s)?

#### Q-2: GAPS AND CHALLENGES

Could you please identify the 3 main gaps and challenges?

#### Q-3: OPPORTUNITIES

Does your country or you as the Focal Point of Veterinary Products intend to improve your regulatory system?

If yes, please exchange with other countries the required, trainings, workshop .....etc to identify the needs?

#### Q-4: JOINT COMMITMENT

Please suggest any possible joint commitment based on the questions above.













# **Groups & Facilitators**

G-1

Botswana

Mozambique

Rwanda

Malawi

Mauritius

G-2

Ghana

eSwatini

Somalia

Zambia

Uganda

G-3

Kenya

South Africa

South Sudan

Zimbabwe

Lesotho

Egypt

G-4

Nigeria

Namibia

**Tanzania** 

Liberia

Seychelles















Mária Szabó

F-2

Jane Lwoyero

A. Aboderin

F-3

Liezl Kock

Ana Mateus

F-4

Francesco Valentini

**Mohamed Sirdar** 









A. Ayoyi



Training Seminar for National Veterinary Products Focal Points





G-D (3): Developing a draft action plan by mapping the needs & opportunities and reshaping the future of VP focal points seminars











Rapporteurs: Mohamed Sirdar Jane Lwoyero



**G-1** 

Outcomes of **Group discussion** (1) on quality of **VMPs** 

**G-2** 

**Outcomes of** Group Discussion (2) on Regulations **G-3** 

**Antimicrobials Antiparasitic and** AMR

**G-4** 

**AMU** 

**G-5** 

**SFVPs** 

**G-6** 

Research and Capacity **Building** 

Botswana Rwanda Seychelles

Somalia South Africa Kenya

Ghana

Namibia Nigeria South Sudan Zimbabwe

Egypt Fritrea Tanzania Zambia

eSwatini Ethiopia? Malawi Liberia

Lesotho **Mauritius** Uganda

F-1: G. Thobokwe

F-2: A. Ayoyi

F-3: M. Szabó

F-4: F. Valentini

F-5: A. Mateus

F-6: M. Letshwenyo















# Group (1): Quality of VMPs

- ➤ Please work on developing a draft action plan (DAP) based on the outcomes of Group Discussion (1) on quality of VMPs.
- > The template below is provided

























# **Group (2): Registrations**

- ➤ Please work on developing a draft action plan (DAP) based on the outcomes of Group Discussion (2) on Registrations.
- > The template below is provided















05 - 07 September 2023 Lilongwe, Malawi













### **Group (3): Antimicrobials/Antiparasitic and AMR**

- Please work on developing a draft action plan (DAP) based on presentations and discussion on Antimicrobials/Antiparasitic and AMR.
- > The template below is provided

















### **Group (4): ANIMUSE**

- > Discuss roles and responsibilities of relevant stakeholders on AMU monitoring system
  - Who will use the data?
  - how data will be used?
  - How will the data collected be shared and reported (data visualisation and dissemination)?





















#### Group (5): SFVPs

#### > SITUATIONAL ANALYSIS:

- Does your country have a system in place for detecting and reporting of SFVPs? If so, what are the challenges for detecting, reporting and responding to SFVPs in your country if any?
- GOVERNANCE OF SFVPs
- In which countries the monitoring /surveillance of quality of vet products (hence detection of SFVPs) is under MoA remit and in which under MoH remit or both?
- Is there communication between MoA and MoH in regard to SFVP in real time? How can WOAH connect both ministries to ensure that FPVP is aware of it?
- ACTION PLAN
- Could countries collaborate to build a laboratory network for the analysis of SFVPs in already established regional networks (i.e. SADC, EAC, etc)? what networks are already in place.
- Should a specific workshop focused on SFVPs be organised? If so, who should be the audience (i.e. only FPVP or also counterparts from MoH, Customs,...)













# **Group (6): Research and Capacity Building**

What are the challenges and research gaps that you have How research can be used to identify gap?











# Thank you

12, rue de Prony, 75017 Paris, France

T. +33 (0)1 44 15 19 49 F. +33 (0)1 42 67 09 87

woah@woah.int www.woah.org <u>Facebook</u>

<u>Twitter</u>

Instagram

<u>LinkedIn</u>

YouTube

Flickr





Veterinary Products: A Vital Tool for Improving Animal Health and Welfare 05 – 07 September 2023 Lilongwe, Malawi